( e incidence of pre-cancerous andpotent...)Gardasil Demonstrates Up to 100% Efficacy,Health

e incidence of pre-cancerous and potentially pre-cancerous cervical lesions (CIN 1-3), pre-cancerous and potentially pre-cancerous vulvar and vaginal lesions (VIN1-3 and VaIN1-3) and external genital warts caused by the Human Papillomavirus types 6, 11, 16 and 18. FUTURE II evaluated the prevention of pre-cancerous cervical lesions (CIN 2/3) and non-invasive cancers (AIS) caused by Human Papillomavirus types 16 and 18.
c) 20,541 women (16-26 years) from the Americas, Europe and Asia were enrolled in one of four trials. In one trial, subjects were randomised to either a monovalent Human Papillomavirus 16 vaccine or placebo. In 3 trials, subjects were randomised to either Gardasil® (types 6/11/16/18) or placebo. For all trials, vaccination occurred at day 1, and months 2 and 6. The primary endpoint was the combined incidence of Human Papillomavirus types 16/18-related CIN 2/3, AIS, or cervical cancer. In the Human Papillomavirus 16 vaccine study, only Human Papillomavirus 16-related cases were considered. Analyses were done in a per protocol (PP) population (subjects received 3 doses, had no major protocol violations, were Human Papillomavirus 16/18 seronegative at day 1 and Human Papillomavirus 16/18 DNA negative Day 1 through month 7). Endpoint counts began at Month 7.
References

'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer